Form 4: Zimmer Biomet Director Maria Teresa Hilado Reports Acquisition of Phantom Stock Units

Director Maria Teresa Hilado reports acquiring phantom stock units in Zimmer Biomet Holdings, Inc. through a deferred compensation plan.

Summary

• Maria Teresa Hilado, a director of Zimmer Biomet Holdings, Inc., filed a Form 4 on April 2, 2024, reporting a transaction that occurred on March 31, 2024.
• The transaction involved the acquisition of 207.156 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The price of the phantom stock units was $132.75.
• Following the reported transaction, Hilado beneficially owns 7,601.702 phantom stock units.
• These units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
• The reported holdings include 13.657 phantom stock units accrued on January 31, 2024, under the dividend reinvestment provision of the plan.

Sentiment

Score: 7

Explanation: The document reflects a neutral sentiment as it is a standard regulatory filing detailing a routine transaction. The acquisition of phantom stock units is generally a positive sign, indicating alignment of interests between the director and the company's performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with the company's performance.
• The deferred compensation plan allows for long-term wealth accumulation tied to the company's success.

Future Outlook

The phantom stock units will be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

Industry Context

This filing is a routine disclosure related to director compensation and is typical for publicly traded companies. It provides transparency into the equity holdings of company insiders.

Comparison to Industry Standards

• Deferred compensation plans are a common practice among publicly traded companies to attract and retain qualified directors.
• The structure of the Zimmer Biomet plan, with cash settlement in installments after service, is consistent with industry norms.
• Comparing the amount of phantom stock units held by Maria Teresa Hilado to those held by directors of comparable companies (e.g., Stryker, Johnson & Johnson) would provide further context, but that data is not available in this document.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term performance.

Key Dates